about
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencingSpread of artemisinin resistance in Plasmodium falciparum malariaArtemisinin-resistant malaria: research challenges, opportunities, and public health implicationsDevelopment of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malariaGenome-wide and fine-resolution association analysis of malaria in West AfricaGenetic architecture of artemisinin-resistant Plasmodium falciparumProtection against malaria at 1 year and immune correlates following PfSPZ vaccinationExternal quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillanceDefining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approachPlasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trialWorld Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria.A network to monitor antimalarial drug resistance: a plan for moving forward.New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in MaliSafety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali.Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialSulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi.Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.A research agenda to underpin malaria eradication.Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.High levels of Plasmodium falciparum rosetting in all clinical forms of severe malaria in African children.Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children.The Jeremiah Metzger lecture: new additions to the toolbox for global malaria eradication.Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccineHLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls.A microarray platform and novel SNP calling algorithm to evaluate Plasmodium falciparum field samples of low DNA quantity.Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites.Reduced T regulatory cell response during acute Plasmodium falciparum infection in Malian children co-infected with Schistosoma haematobium.Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children.Stable malaria incidence despite scaling up control strategies in a malaria vaccine-testing site in Mali.Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Antigen-specific B memory cell responses to Plasmodium falciparum malaria antigens and Schistosoma haematobium antigens in co-infected Malian childrenA longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemiaA high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDaSuccessful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection.Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype.Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.
P50
Q20901697-323E346F-00EA-4B5E-BDD0-B69146A33C77Q21032481-B9457A0C-664F-449F-9C66-D7175C6BCD55Q21032532-9883B84B-390E-4001-87DB-D2F16F42A9C8Q21032534-9C764A98-1105-4D71-8283-F91E2E5EE681Q24632119-75C16687-5D95-4259-AA3C-22C40E316768Q28030935-4E48BA1D-3865-4507-A000-D8D20BA1FD0DQ28049695-76911F0F-7DF3-4FA1-BECA-45AB00219B21Q28538917-40810E63-B91F-40F5-9A21-93F77CC234FBQ28546794-13DA28A9-5CD4-4828-A716-5EA604DD0A3CQ28748765-EE4D70D5-6B3E-4879-BED5-EBC7CB80E310Q30483555-D8799D8C-79CE-446B-BF7F-9E5536FE3CD5Q30483616-D60EB95E-7F25-417B-A8E9-945AE41756E3Q30843121-25E4C50E-603C-46A2-82BD-44BF343BF57BQ33264523-B5554EE2-19E1-4CE6-A535-D22D473632CDQ33278087-8D886D47-FB9B-48EC-9A8A-26AF4C74733AQ33316023-C58C9F6E-1DC1-4624-AF73-694BFD06C916Q33319559-A5FDF720-DB77-4BC4-AB3D-57BAB9565FCBQ33530106-769604AE-9961-40AE-A32A-F4DC2599C67EQ33654911-768AA20B-8B65-4FE5-8AF0-AC47CC2B65D1Q33818020-ABA6BC06-034A-4205-BB93-803D7A8CC554Q33846126-4475E4A5-84B5-4243-8008-3C989FE1F13CQ33881768-E288B564-1906-4537-A2E0-3489F04B90E4Q33935430-FBA5068A-D164-4357-9D43-1105B26F4FAAQ33957657-840181BC-B21E-49EC-829D-7C452BABA8A0Q34011922-45D24112-D48C-4B55-814C-69E9180EE6F5Q34034148-897095AF-3C47-4B09-A828-AA6D569384A3Q34130050-3330922C-B075-43D2-8181-C2FE838A41AFQ34138437-8788771B-3AB4-4558-BD85-2B5698AE3BCCQ34163676-99831C26-7DE3-4AF9-8915-9683ED684864Q34229701-60F37D55-1C2B-42D5-8DF2-A52BEC242E57Q34271312-BC0DAA6D-DFD5-4840-A0A8-BF3EC219038BQ34281680-27EADB57-9886-49DB-A7C9-9A30F376D4DEQ34302523-0CD3737B-F52C-40DB-8743-35511D830081Q34388722-D546B5AC-0A1C-44AC-920A-1D46544E5252Q34401225-E5B9EFB2-2C50-4004-B9B5-5CE116127F68Q34568283-990EC82A-DABE-469F-8178-A9DBE947744FQ34602857-60436204-0C35-43B0-8DC8-8D742DF510D0Q34852105-03804A08-F96F-4F20-845D-FE84CCCE64EDQ35047872-C716C049-37D3-4878-BBE0-FE76A60F231EQ35048336-E206E8CF-9F2D-44B3-ACE2-7170111829C7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Christopher V Plowe
@ast
Christopher V Plowe
@en
Christopher V Plowe
@es
Christopher V Plowe
@nl
Christopher V Plowe
@sl
type
label
Christopher V Plowe
@ast
Christopher V Plowe
@en
Christopher V Plowe
@es
Christopher V Plowe
@nl
Christopher V Plowe
@sl
prefLabel
Christopher V Plowe
@ast
Christopher V Plowe
@en
Christopher V Plowe
@es
Christopher V Plowe
@nl
Christopher V Plowe
@sl